Session Abstract – PMWC 2022 Silicon Valley


  • UC Precision Medicine Programs: Achievements and Challenges
    Session Chair: India Hook-Barnard, EBRC
    - Keith Yamamoto, UCSF
    - Clara Lajonchere, UCLA
    - Frederick J Meyers, UC Davis Health
  • Fireside Chat with Conrad Vial, Sutter Health and Precision Medicine Practices
    - Conrad Vial, Sutter Health
    - Erika Vial-Monteverdi, RotaCare Clinics
  • Precision Approaches to Chronic Disease (PANEL)
    Session Chair: Jennifer Lovejoy, Seven.me
    - Noel Mueller, Johns Hopkins
    - Maureen K. O'Connor, ZealCare
    - Sunjya K. Schweig, California Center For Functional Medicine (CCFM)
  • DNA-based Weight Loss Interventions: What Have We Learned? (PANEL)
    Session Chair: Jennifer Lovejoy, Seven.me
    - George Bray, Pennington Biomedical Research Center
    - Christopher Gardner, Stanford
  • Advances in Digital Health, Diabetes and Obesity Management (PANEL)
    Session Chair: Mike Snyder, Stanford
    - Jessilyn Dunn, Duke University
    - Jonathan Long, Stanford
    - James Galagan, Boston University
  • Illumina Accelerator Innovation
    Session Chair: Amanda Cashin, Illumina Accelerator
    - Trevor Levin, Convergent Genomics
    - Rhidi Tariyal, NextGen Jane
    - Kareem Barghouti, VastBiome
  • PMWC Showcase
    - Jarret Glasscock, Cofactor Genomics
    - David Hanna, Thermo Fisher

 Session Chair Profile

Ph.D., Chair, Department of Genetics, Stanford University

Biography
Dr. Snyder received his Ph.D. training at the California Institute of Technology and carried out postdoctoral training at Stanford University. He is a leader in the field of functional genomics and multiomics, and one of the major participants of the ENCODE project. His laboratory was the first to perform a large-scale functional genomics project in any organism, and has developed many technologies in genomics and proteomics. Seminal findings from the Snyder laboratory include the discovery that much more of the human genome is transcribed and contains regulatory information than was previously appreciated (e.g. lncRNAs and TF binding sites), and a high diversity of transcription factor binding occurs both between and within species. He launched the field of personalized medicine by combining different state-of–the-art “omics” technologies to perform the first longitudinal detailed integrative personal omics profile (iPOP) of a person, and his laboratory pioneered the use of wearables technologies (smart watches and continuous glucose monitoring) for precision health.


 Session Chair Profile

Ph.D., Co-Founder & Head, Illumina Accelerator

Biography
Amanda Cashin is Co-Founder and Head of Illumina Accelerator, a leading company creation engine and investment vehicle focused on building genomics-driven startups. Founded in Fall 2014 in San Francisco, Illumina Accelerator has invested in over 10 startups advancing breakthrough applications in genomics, including applications in therapeutics, women’s health, cancer diagnostics, consumer nutrition, agriculture, synthetic biology, and skin microbiome. Previously, Amanda was Senior Vice President of Alexandria Venture Investments at Alexandria Real Estate Equities, Inc. Amanda also led a team of life science professionals with strong science and business expertise responsible for industry research, company analysis, business development, and thought leadership activities to help position Alexandria at the forefront of the industry. She earned a Ph.D. in Chemical Biology from the California Institute of Technology. Her scientific expertise and peer-reviewed publications are in the fields of biochemistry, organic chemistry, physical chemistry, pharmacology, electrophysiology, and neuroscience.


 Session Chair Profile

Ph.D., Deputy Director UCLA Institute for Precision Health, UCLA

Biography
Clara Lajonchere, PhD is the Deputy Director for the UCLA Institute for Precision Health, Co-Director of the Clinical Neurogenetic Research Program, and Adjunct Professor of Neurology in the David Geffen School of Medicine at UCLA. Dr. Lajonchere’s background reflects a wide range of professional, clinical, and research activities across central nervous system disorders. She has spent her career on cross-cutting issues in psychiatric genetics and translational medicine. Through the UCLA Institute for Precision Health, Dr. Lajonchere is working collaboratively with thought leaders across the state of California to advance precision medicine and improve outcomes for patients. She currently serves as chair of the California Precision Medicine Advisory Council for the Governor’s Office of Planning and Research.


 Speaker Profile

Ph.D.,M.P.H., Assistant Professor, Johns Hopkins Bloomberg School of Public Health

Biography
I am a tenure-track Assistant Professor in the Department of Epidemiology at Johns Hopkins Bloomberg School of Public Health, a Core Faculty member in the Welch Center for Prevention, Epidemiology and Clinical Research. My research examines the nutritional, microbial, and environmental determinants of health across the lifespan, with the ultimate goal of identifying modifiable targets for chronic disease prevention and treatment. I believe that primary prevention of disease risk factors, in early life and among high-risk populations, provides the greatest opportunity to curb contemporary chronic disease epidemics and reduce health disparities. Accordingly, many of my investigations, in both local and global contexts, are in young, racially and ethnically diverse populations. A large part of my research focuses on the role of the human microbiome in nutrition and disease. I am particularly intrigued by the microbiome because it is amenable to intervention.

Talk
Sharpening Nutrition Science with the Microbiome
In this talk I will provide an overview of how the intestinal microbiota and their metabolites can inform more precise approaches to prevention and treatment of nutrition-related cardiometabolic diseases, including obesity, type 2 diabetes and obesity in both children and adults.


 Speaker Profile

M.D., Boyd Professor Emeritus, Pennington Biomedical Research Center

Biography
George A. Bray, M.D., founded the International Journal of Obesity in 1976, Chaired the 2nd International Congress on Obesity in 1977, founded the Obesity Society (NAASO) in 1981 and the journal Obesity in 1993. In 1989 he became the 1st Executive Director of the Pennington Biomedical Research Center. Among his many awards is the Presidential Medal from The Obesity Society and the 2019 Wilbur O Atwater Award from the USDA and ASN. Bray authored than 1,000 publications.

Talk
Lessons Learned from the POUNDS Lost Study
The POUNDS Lost study measured weight loss in 811 individuals assigned to 20% or 40% fat and 15% and 25% protein diets. Weight loss was not different between diet but there was a large variance. This study provides many lesson on interaction of diet with genetic and non-genetic factors.


 Speaker Profile

Ph.D., Rehnborg Farquhar Professor of Medicine, Stanford University

Biography
For ~30 years Christopher Gardner has studied what to consume and to avoid for optimal health, and how best to motivate individuals to achieve healthy dietary behaviors. Some of the dozens of human nutrition intervention trials he has conducted include studies of garlic, omega-3 fats, soy phytoestrogens and antioxidants. Among his most cited studies are the A TO Z (JAMA 2007) and the DIETFITS (JAMA 2018) weight loss diet trials. The DIETFITS trial examined the possibility that a 3-SNP multilocus genotype would predict differential weight loss success on a Healthy-Low-Fat vs. a Healthy-Low-Carb diet among more than 600 overweight and obese adults. His interests in this area of personalized nutrition continue with his participation in the Trans-NIH Consortium: Randomized Controlled Trials of Lifestyle Weight Loss Interventions for Genome-wide Association Studies. He is also working on personalized nutrition explorations with other investigators.

Talk
DNA-based Weight Loss Interventions: What Have We Learned?
The 2018 DIETFITS study tested the hypothesis that a 3-SNP genotype pattern would be an effect modifier of weight loss on a healthy low-fat vs. a healthy low-carb diet. The hypothesis was not supported. NIH convened a consortium too look at this question across studies. What have they learned?


 Speaker Profile

M.D., Founder and President, CCFM

Biography
Sunjya K. Schweig, MD, is Founder and President of the California Center for Functional Medicine (CCFM). CCFM provides personalized, precision medicine care that is fundamental for managing patients with chronic illness. CCFM integrates a comprehensive care team with cutting edge technology and data. This high-touch and high-tech approach offers patients the optimal opportunity for prevention and recovery from complex chronic illness. As a global leader in the functional medicine movement, since 2016 CCFM has been honored to run comprehensive wellness programs for first responders to help mitigate the unique occupational risks that they experience. A graduate of the University of California, Berkeley, Dr. Schweig completed his MD at the University of California, Irvine, and his family medicine residency at the University of California, San Francisco (UCSF), Family Practice Residency Program in Santa Rosa, CA. He is board certified in family practice (ABFM) and integrative and holistic medicine (ABIHM).


 Speaker Profile

J.D., CEO, ZealCare

Biography
Maureen O’Connor is a senior healthcare executive passionate about driving change in our health care system to improve lives. Currently, she served as CEO of ZealCare, an early stage health care services and technology company, spun out of Duke, with a mission to empower people with complex chronic conditions to live the life they want. The company provides intensive, individualized support to participants and their care team through personalized planning, education and virtual group visits. Initially, Zeal is targeting individuals with chronic kidney disease and type 2 diabetes. Formerly, Maureen served as president of Whiterabbit.ai, a Silicon Valley company with a mission to eradicate late-stage breast cancer through the use of artificial intelligence. Maureen spent 17 years as an executive with Blue Cross Blue Shield of North Carolina, serving as EVP of diversified businesses, president of Mosaic Health Solutions, and chief strategy and innovation officer.


 Speaker Profile

M.D., SVP, Chief Clinical Officer & Cardiothoracic Surgeon, Sutter Health

Biography
As Sutter Health’s Chief Clinical Officer, Dr. Vial responsibilities include the development of clinical strategy, research and graduate medical education, quality and safety, digital patient engagement and patient experience. Dr. Vial is a practicing cardiothoracic surgeon who has held various leadership roles in multispecialty medical group practice and integrated healthcare delivery. From the clinical practice perspective, Dr. Vial is particularly interested in structural heart disease, focusing on minimally invasive cardiothoracic surgery and catheter-based valve repair and replacement. Dr. Vial received his bachelor’s degree and medical doctorate from Stanford University. He earned a master’s of philosophy at Cambridge University in England, while also completing a postdoctoral fellowship in transplant immunology. He conducted his general surgical and cardiothoracic surgical training at Stanford University Medical Center. He has been board certified in both general surgery and cardiothoracic surgery.

Talk
The Fusion of Healthcare Delivery and High Tech
When we say precision medicine, what is it that we are going to be precise about, and how does it help both patients and physicians? Tech thinks about users and providers think about patients. How can such differences be harnessed to learn from one another and work together to build and deploy effective precision medicine?


 Speaker Profile

M.B.A., Strategic Advisor, RotaCare Clinics

Biography
Erika is advises for-profit and non-profit healthcare start-up companies. She was the Executive Director of Cancer Commons, one of Silicon Valley’s only nonprofits focused on serving cancer patients globally through aligning incentives around the patient to produce better outcomes. Erika also helped spin out a for-profit health technology company, xCures, which uses artificial intelligence (A.I.) and predictive modeling to identify and rank the most promising treatment options for people with cancer who have exhausted the standard of care. She also serves as an Advisor to the for-profit company, StuffThatWorks.health, using smart, AI-based crowdsourcing to help people learn which treatments work best for their condition, and serves as Advisor to the Board of RotaryCare Free Clinics.

Talk
The Fusion of Healthcare Delivery and High Tech
When we say precision medicine, what is it that we are going to be precise about, and how does it help both patients and physicians? Tech thinks about users and providers think about patients. How can such differences be harnessed to learn from one another and work together to build and deploy effective precision medicine?


 Speaker Profile

Ph.D., Assistant Professor of Pathology, Stanford University

Biography
At Stanford, the Long laboratory studies the signaling pathways that control mammalian energy metabolism. Dr. Long’s contributions in the areas of metabolism and energy homeostasis have been recognized by numerous awards including the NIDDK DP1 Catalyst Award, the NIH Pathways to Independence Award, and the Ono Pharma Foundation Breakthrough Sciences Award. The long-term goal of this work is to discover new molecules and physiologic pathways that can be translated into therapeutic opportunities for obesity, metabolic disease, and other age-associated chronic diseases.


 Speaker Profile

Ph.D., Assistant Professor, Duke University

Biography
Jessilyn Dunn is the Director of the Duke BIG IDEAs Laboratory which is focused on biomedical data science and mobile health for digital biomarker discovery. Dr. Dunn is PI of the CovIdentify study to detect and monitor COVID-19 using mobile health technologies, which is built upon the team’s previous infection detection work through the DARPA Prometheus and Biochronicity programs. Dr. Dunn was an NIH Big Data to Knowledge (BD2K) Postdoctoral Fellow at Stanford, an NSF Graduate Research Fellow at Georgia Tech & Emory, and a visiting scholar at the CDC and the National Cardiovascular Research Institute in Madrid, Spain. Her work has been internationally recognized with media coverage from the NIH Director’s Blog to Wired, Time, and US News and World Report.


 Speaker Profile

CEO, VastBiome

Biography
Kareem Barghouti is the co-founder and CEO of VastBiome. He received his B.S. in Biological Sciences at UC Irvine and a MBA from Duke University with a concentration in Healthcare Sector Management. His background is in Strategy & Operations and Sales & Marketing. Kareem was part of a fast-growing tech startup that Google. He spent 5 years at Google leading the data integrity of Google’s advertising business and was part of the core product team to launch an online education portal to millions of users globally. He was recognized as one of the top sales rep globally (1000+ reps) for the New Business Sales team. Most recently, Kareem participated as a Biodesign Fellow at the Texas Medical Center Innovation Institute in Houston, Texas, where VastBiome was born.


 Speaker Profile

CEO, NextGen Jane

Biography
Ridhi Tariyal, co-founder and CEO of NextGen Jane. Before founding NextGen Jane, Ridhi led the operations and finances of a $10M genomic endeavor in West Africa for the Broad Institute. Most of Ridhi's career has been in healthcare, from operational roles in a big pharmaceutical company (Bristol-Myers Squibb) to smaller entrepreneurial organizations (Embrace).


 Speaker Profile

Ph.D., Professor, Boston University

Biography
The Galagan lab is an interdisciplinary lab with expertise in genomics and next-generation sequencing, molecular biology and microbiology, computational biology, and various engineering disciplines. The lab performs research and develops biomedical applications at the interface of engineering, computer science, molecular biology and microbiology. Dr. Galagan pioneered the concept of screening bacteria for molecular sensing proteins and developing these proteins into electronic sensors. He leads an interdisciplinary collaboration among colleagues at Boston University to develop and commercialize a range of applications based on these novel biosensors.


 Speaker Profile

Ph.D., CEO, Cofactor Genomics

Biography
Jarret Glasscock is a geneticist and computational biologist. Prior to co-founding Cofactor Genomics, Jarret was faculty in the Department of Genetics at Washington University and part of The Genome Institute. While at WashU, he was involved in the Human Genome Project, published the first Cancer Genome, lead the Institute’s Computational Biology Group, and was part of the Institute’s Technology Development Group tasked with characterizing the first RNA-seq experiments on early instruments such as 454 and Illumina/Solexa(Serial #1). Jarret’s work to leverage signals in RNA to propel Precision Medicine Initiatives has been covered by Genetic Engineering News (GEN), Tech Crunch, STAT News, and Wired Magazine. He is a member of the Personalized Medicine Coalition, International Society for Computational Biology, American Association for Cancer Research and is a Y Combinator Alum.


 Speaker Profile

M.D., Professor; Director Center for Precision Medicine and Data Sciences, UC Davis Health

Biography
Dr. Frederick Meyers is Distinguished Professor of Internal Medicine at UC Davis Health. His career interests include multifaceted investigations of advanced cancer and training the next generation of scientists. He has served UC Davis as Chief of Hematology/Oncology, Chair of the Department of Internal Medicine and Vice Dean of the School of Medicine. He currently leads the Center for Precision Medicine and Data Sciences. Additionally, he is Associate Director for Education, Training and Career Development for our Comprehensive Cancer Center, and he founded "Academic Research Careers for Medical Doctors (ARC-MD)", a medical school pathway to train the next generation of diverse faculty. Dr. Meyers' national leadership in career development has been recognized with many training grants, service to NIH, and as President of the Association of Clinical and Translational Science 2019-2020. In 2020 he received the Chancellor’s Achievement Award for Diversity and Community Service.

Talk
A Comprehensive University Vision For Precision Medicine
Precision Medicine and Data Sciences at a comprehensive university promotes new teams by uniting heath care and population health with training and career development, with seven colleges, and valued community partners.


 Speaker Profile

Ph.D., Director of Business Development, Thermo Fisher Scientific

Biography
Primary focus of work is global market development in the predictive genomics space. Engaging with organizations and institutions seeking to implement a full program - from sample collection to physician/patient reporting - using a patient’s whole genome data for common disease risk and ADR (adverse drug reaction) risk prediction. Working to establish a functioning ecosystem and workflows that show healthcare providers a path to implementing such programs system-wide and at scale.

Talk
Implement Predictive Genomics Today, Improve Healthcare’s Tomorrow
Healthcare costs represent an outsized portion of all developed country’s GDP. Predictive genomic posits that keeping populations healthier allows providers to manage patient health rather than manage disease. Risk prediction through whole genome profiling of healthy individuals is the key.


 Speaker Profile

Ph.D., Co-founder and CEO, Convergent Genomics

Biography
Our future world will be one in which your unique biology (genome, cellular and organ function, health status and disease risk factors) can be measured with unprecedented resolution and translated into petabytes of data. Recent breakthroughs in measurement technology now permit the cost effective sequencing of human genomes, new understanding of the complex ecosystems of microbes that live within us, and new resolution on how our environment and life styles modulate our genomic and cellular health over time. The promise of biology's information revolution is a world in which the diverse causes of disease are better understood and prevented, nutrition and medicines are intelligently personalized to individuals unique biology, and currently lethal diseases (such as late stage cancers) are detected early when they can be treated effectively and cured. Maximizing this revolutions potential will require the development of new medical and research fields, new computational approaches and data management systems, new legal and ethical frameworks, and new ways for "crowds" or global communities of researchers to share and collaboratively untangle this unprecedented torrent of data. Within this backdrop, my work is dedicated to improving the lives of cancer patients through the discovery of better treatments and methods of earlier detection. I use next generation sequencing and novel computational approaches to predict drug response and develop diagnostics for minimally invasive and early detection of cancer. My technical expertise is complemented by a scrappy, resourceful drive to build great companies from scratch - entrepreneurship - with the goal of translating laboratory discovery into viable clinical products for the benefit of cancer patients.